Research ArticleArticle
The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis
Tanaz A. Kermani, David Cuthbertson, Simon Carette, Gary S. Hoffman, Nader A. Khalidi, Curry L. Koening, Carol A. Langford, Kathleen McKinnon-Maksimowicz, Carol A. McAlear, Paul A. Monach, Philip Seo, Kenneth J. Warrington, Steven R. Ytterberg, Peter A. Merkel and Eric L. Matteson
The Journal of Rheumatology April 2016, jrheum.151063; DOI: https://doi.org/10.3899/jrheum.151063
Tanaz A. Kermani
From the Division of Rheumatology, University of California, Los Angeles, Los Angeles, California; Department of Biostatistics, University of South Florida, Tampa, Florida, USA; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada; Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio, USA; Division of Rheumatology, St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario, Canada; Division of Rheumatology, University of Utah, Salt Lake City, Utah; Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Division of Rheumatology and Clinical Immunology, University of Pennsylvania, Philadelphia, Pennsylvania; The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Dr. Kermani was supported through a Vasculitis Fellowship by the Vasculitis Clinical Research Consortium (VCRC). The VCRC has received support from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the US National Center for Research Resources (U54 RR019497), the Office of Rare Diseases Research, and the US National Center for Advancing Translational Science. The VCRC is part of the Rare Diseases Clinical Research Network. T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; D. Cuthbertson, MS, Department of Biostatistics, University of South Florida; S. Carette, MD, FRCPC, Division of Rheumatology, Mount Sinai Hospital; G.S. Hoffman, MD, MS, Center for Vasculitis Care and Research, Cleveland Clinic; N.A. Khalidi, MD, FRCPC, Division of Rheumatology, St. Joseph’s Healthcare, McMaster University; C.L. Koening, MD, MS, Division of Rheumatology, University of Utah; C.A. Langford, MD, MHS, Center for Vasculitis Care and Research, Cleveland Clinic; K. McKinnon-Maksimowicz, DO, Division of Rheumatology, University of Pittsburgh; C.A. McAlear, MA, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; P.A. Monach, MD, PhD, The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine; P. Seo, MD, MHS, Division of Rheumatology, Johns Hopkins University; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic College of Medicine; S.R. Ytterberg, MD, Division of Rheumatology, Mayo Clinic College of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; E.L. Matteson, MD, MPH, Division of Rheumatology, Mayo Clinic College of Medicine. Address correspondence to Dr. T.A. Kermani, University of California, Los Angeles, 2020 Santa Monica Blvd., Suite 540, Santa Monica, California 90404, USA. E-mail: kermani.tanaz@yahoo.com. Accepted for publication February 26, 2016.
David Cuthbertson
From the Division of Rheumatology, University of California, Los Angeles, Los Angeles, California; Department of Biostatistics, University of South Florida, Tampa, Florida, USA; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada; Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio, USA; Division of Rheumatology, St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario, Canada; Division of Rheumatology, University of Utah, Salt Lake City, Utah; Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Division of Rheumatology and Clinical Immunology, University of Pennsylvania, Philadelphia, Pennsylvania; The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Dr. Kermani was supported through a Vasculitis Fellowship by the Vasculitis Clinical Research Consortium (VCRC). The VCRC has received support from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the US National Center for Research Resources (U54 RR019497), the Office of Rare Diseases Research, and the US National Center for Advancing Translational Science. The VCRC is part of the Rare Diseases Clinical Research Network. T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; D. Cuthbertson, MS, Department of Biostatistics, University of South Florida; S. Carette, MD, FRCPC, Division of Rheumatology, Mount Sinai Hospital; G.S. Hoffman, MD, MS, Center for Vasculitis Care and Research, Cleveland Clinic; N.A. Khalidi, MD, FRCPC, Division of Rheumatology, St. Joseph’s Healthcare, McMaster University; C.L. Koening, MD, MS, Division of Rheumatology, University of Utah; C.A. Langford, MD, MHS, Center for Vasculitis Care and Research, Cleveland Clinic; K. McKinnon-Maksimowicz, DO, Division of Rheumatology, University of Pittsburgh; C.A. McAlear, MA, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; P.A. Monach, MD, PhD, The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine; P. Seo, MD, MHS, Division of Rheumatology, Johns Hopkins University; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic College of Medicine; S.R. Ytterberg, MD, Division of Rheumatology, Mayo Clinic College of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; E.L. Matteson, MD, MPH, Division of Rheumatology, Mayo Clinic College of Medicine. Address correspondence to Dr. T.A. Kermani, University of California, Los Angeles, 2020 Santa Monica Blvd., Suite 540, Santa Monica, California 90404, USA. E-mail: kermani.tanaz@yahoo.com. Accepted for publication February 26, 2016.
Simon Carette
From the Division of Rheumatology, University of California, Los Angeles, Los Angeles, California; Department of Biostatistics, University of South Florida, Tampa, Florida, USA; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada; Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio, USA; Division of Rheumatology, St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario, Canada; Division of Rheumatology, University of Utah, Salt Lake City, Utah; Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Division of Rheumatology and Clinical Immunology, University of Pennsylvania, Philadelphia, Pennsylvania; The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Dr. Kermani was supported through a Vasculitis Fellowship by the Vasculitis Clinical Research Consortium (VCRC). The VCRC has received support from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the US National Center for Research Resources (U54 RR019497), the Office of Rare Diseases Research, and the US National Center for Advancing Translational Science. The VCRC is part of the Rare Diseases Clinical Research Network. T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; D. Cuthbertson, MS, Department of Biostatistics, University of South Florida; S. Carette, MD, FRCPC, Division of Rheumatology, Mount Sinai Hospital; G.S. Hoffman, MD, MS, Center for Vasculitis Care and Research, Cleveland Clinic; N.A. Khalidi, MD, FRCPC, Division of Rheumatology, St. Joseph’s Healthcare, McMaster University; C.L. Koening, MD, MS, Division of Rheumatology, University of Utah; C.A. Langford, MD, MHS, Center for Vasculitis Care and Research, Cleveland Clinic; K. McKinnon-Maksimowicz, DO, Division of Rheumatology, University of Pittsburgh; C.A. McAlear, MA, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; P.A. Monach, MD, PhD, The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine; P. Seo, MD, MHS, Division of Rheumatology, Johns Hopkins University; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic College of Medicine; S.R. Ytterberg, MD, Division of Rheumatology, Mayo Clinic College of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; E.L. Matteson, MD, MPH, Division of Rheumatology, Mayo Clinic College of Medicine. Address correspondence to Dr. T.A. Kermani, University of California, Los Angeles, 2020 Santa Monica Blvd., Suite 540, Santa Monica, California 90404, USA. E-mail: kermani.tanaz@yahoo.com. Accepted for publication February 26, 2016.
Gary S. Hoffman
From the Division of Rheumatology, University of California, Los Angeles, Los Angeles, California; Department of Biostatistics, University of South Florida, Tampa, Florida, USA; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada; Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio, USA; Division of Rheumatology, St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario, Canada; Division of Rheumatology, University of Utah, Salt Lake City, Utah; Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Division of Rheumatology and Clinical Immunology, University of Pennsylvania, Philadelphia, Pennsylvania; The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Dr. Kermani was supported through a Vasculitis Fellowship by the Vasculitis Clinical Research Consortium (VCRC). The VCRC has received support from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the US National Center for Research Resources (U54 RR019497), the Office of Rare Diseases Research, and the US National Center for Advancing Translational Science. The VCRC is part of the Rare Diseases Clinical Research Network. T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; D. Cuthbertson, MS, Department of Biostatistics, University of South Florida; S. Carette, MD, FRCPC, Division of Rheumatology, Mount Sinai Hospital; G.S. Hoffman, MD, MS, Center for Vasculitis Care and Research, Cleveland Clinic; N.A. Khalidi, MD, FRCPC, Division of Rheumatology, St. Joseph’s Healthcare, McMaster University; C.L. Koening, MD, MS, Division of Rheumatology, University of Utah; C.A. Langford, MD, MHS, Center for Vasculitis Care and Research, Cleveland Clinic; K. McKinnon-Maksimowicz, DO, Division of Rheumatology, University of Pittsburgh; C.A. McAlear, MA, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; P.A. Monach, MD, PhD, The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine; P. Seo, MD, MHS, Division of Rheumatology, Johns Hopkins University; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic College of Medicine; S.R. Ytterberg, MD, Division of Rheumatology, Mayo Clinic College of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; E.L. Matteson, MD, MPH, Division of Rheumatology, Mayo Clinic College of Medicine. Address correspondence to Dr. T.A. Kermani, University of California, Los Angeles, 2020 Santa Monica Blvd., Suite 540, Santa Monica, California 90404, USA. E-mail: kermani.tanaz@yahoo.com. Accepted for publication February 26, 2016.
Nader A. Khalidi
From the Division of Rheumatology, University of California, Los Angeles, Los Angeles, California; Department of Biostatistics, University of South Florida, Tampa, Florida, USA; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada; Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio, USA; Division of Rheumatology, St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario, Canada; Division of Rheumatology, University of Utah, Salt Lake City, Utah; Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Division of Rheumatology and Clinical Immunology, University of Pennsylvania, Philadelphia, Pennsylvania; The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Dr. Kermani was supported through a Vasculitis Fellowship by the Vasculitis Clinical Research Consortium (VCRC). The VCRC has received support from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the US National Center for Research Resources (U54 RR019497), the Office of Rare Diseases Research, and the US National Center for Advancing Translational Science. The VCRC is part of the Rare Diseases Clinical Research Network. T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; D. Cuthbertson, MS, Department of Biostatistics, University of South Florida; S. Carette, MD, FRCPC, Division of Rheumatology, Mount Sinai Hospital; G.S. Hoffman, MD, MS, Center for Vasculitis Care and Research, Cleveland Clinic; N.A. Khalidi, MD, FRCPC, Division of Rheumatology, St. Joseph’s Healthcare, McMaster University; C.L. Koening, MD, MS, Division of Rheumatology, University of Utah; C.A. Langford, MD, MHS, Center for Vasculitis Care and Research, Cleveland Clinic; K. McKinnon-Maksimowicz, DO, Division of Rheumatology, University of Pittsburgh; C.A. McAlear, MA, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; P.A. Monach, MD, PhD, The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine; P. Seo, MD, MHS, Division of Rheumatology, Johns Hopkins University; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic College of Medicine; S.R. Ytterberg, MD, Division of Rheumatology, Mayo Clinic College of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; E.L. Matteson, MD, MPH, Division of Rheumatology, Mayo Clinic College of Medicine. Address correspondence to Dr. T.A. Kermani, University of California, Los Angeles, 2020 Santa Monica Blvd., Suite 540, Santa Monica, California 90404, USA. E-mail: kermani.tanaz@yahoo.com. Accepted for publication February 26, 2016.
Curry L. Koening
From the Division of Rheumatology, University of California, Los Angeles, Los Angeles, California; Department of Biostatistics, University of South Florida, Tampa, Florida, USA; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada; Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio, USA; Division of Rheumatology, St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario, Canada; Division of Rheumatology, University of Utah, Salt Lake City, Utah; Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Division of Rheumatology and Clinical Immunology, University of Pennsylvania, Philadelphia, Pennsylvania; The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Dr. Kermani was supported through a Vasculitis Fellowship by the Vasculitis Clinical Research Consortium (VCRC). The VCRC has received support from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the US National Center for Research Resources (U54 RR019497), the Office of Rare Diseases Research, and the US National Center for Advancing Translational Science. The VCRC is part of the Rare Diseases Clinical Research Network. T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; D. Cuthbertson, MS, Department of Biostatistics, University of South Florida; S. Carette, MD, FRCPC, Division of Rheumatology, Mount Sinai Hospital; G.S. Hoffman, MD, MS, Center for Vasculitis Care and Research, Cleveland Clinic; N.A. Khalidi, MD, FRCPC, Division of Rheumatology, St. Joseph’s Healthcare, McMaster University; C.L. Koening, MD, MS, Division of Rheumatology, University of Utah; C.A. Langford, MD, MHS, Center for Vasculitis Care and Research, Cleveland Clinic; K. McKinnon-Maksimowicz, DO, Division of Rheumatology, University of Pittsburgh; C.A. McAlear, MA, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; P.A. Monach, MD, PhD, The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine; P. Seo, MD, MHS, Division of Rheumatology, Johns Hopkins University; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic College of Medicine; S.R. Ytterberg, MD, Division of Rheumatology, Mayo Clinic College of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; E.L. Matteson, MD, MPH, Division of Rheumatology, Mayo Clinic College of Medicine. Address correspondence to Dr. T.A. Kermani, University of California, Los Angeles, 2020 Santa Monica Blvd., Suite 540, Santa Monica, California 90404, USA. E-mail: kermani.tanaz@yahoo.com. Accepted for publication February 26, 2016.
Carol A. Langford
From the Division of Rheumatology, University of California, Los Angeles, Los Angeles, California; Department of Biostatistics, University of South Florida, Tampa, Florida, USA; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada; Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio, USA; Division of Rheumatology, St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario, Canada; Division of Rheumatology, University of Utah, Salt Lake City, Utah; Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Division of Rheumatology and Clinical Immunology, University of Pennsylvania, Philadelphia, Pennsylvania; The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Dr. Kermani was supported through a Vasculitis Fellowship by the Vasculitis Clinical Research Consortium (VCRC). The VCRC has received support from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the US National Center for Research Resources (U54 RR019497), the Office of Rare Diseases Research, and the US National Center for Advancing Translational Science. The VCRC is part of the Rare Diseases Clinical Research Network. T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; D. Cuthbertson, MS, Department of Biostatistics, University of South Florida; S. Carette, MD, FRCPC, Division of Rheumatology, Mount Sinai Hospital; G.S. Hoffman, MD, MS, Center for Vasculitis Care and Research, Cleveland Clinic; N.A. Khalidi, MD, FRCPC, Division of Rheumatology, St. Joseph’s Healthcare, McMaster University; C.L. Koening, MD, MS, Division of Rheumatology, University of Utah; C.A. Langford, MD, MHS, Center for Vasculitis Care and Research, Cleveland Clinic; K. McKinnon-Maksimowicz, DO, Division of Rheumatology, University of Pittsburgh; C.A. McAlear, MA, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; P.A. Monach, MD, PhD, The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine; P. Seo, MD, MHS, Division of Rheumatology, Johns Hopkins University; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic College of Medicine; S.R. Ytterberg, MD, Division of Rheumatology, Mayo Clinic College of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; E.L. Matteson, MD, MPH, Division of Rheumatology, Mayo Clinic College of Medicine. Address correspondence to Dr. T.A. Kermani, University of California, Los Angeles, 2020 Santa Monica Blvd., Suite 540, Santa Monica, California 90404, USA. E-mail: kermani.tanaz@yahoo.com. Accepted for publication February 26, 2016.
Kathleen McKinnon-Maksimowicz
From the Division of Rheumatology, University of California, Los Angeles, Los Angeles, California; Department of Biostatistics, University of South Florida, Tampa, Florida, USA; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada; Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio, USA; Division of Rheumatology, St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario, Canada; Division of Rheumatology, University of Utah, Salt Lake City, Utah; Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Division of Rheumatology and Clinical Immunology, University of Pennsylvania, Philadelphia, Pennsylvania; The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Dr. Kermani was supported through a Vasculitis Fellowship by the Vasculitis Clinical Research Consortium (VCRC). The VCRC has received support from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the US National Center for Research Resources (U54 RR019497), the Office of Rare Diseases Research, and the US National Center for Advancing Translational Science. The VCRC is part of the Rare Diseases Clinical Research Network. T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; D. Cuthbertson, MS, Department of Biostatistics, University of South Florida; S. Carette, MD, FRCPC, Division of Rheumatology, Mount Sinai Hospital; G.S. Hoffman, MD, MS, Center for Vasculitis Care and Research, Cleveland Clinic; N.A. Khalidi, MD, FRCPC, Division of Rheumatology, St. Joseph’s Healthcare, McMaster University; C.L. Koening, MD, MS, Division of Rheumatology, University of Utah; C.A. Langford, MD, MHS, Center for Vasculitis Care and Research, Cleveland Clinic; K. McKinnon-Maksimowicz, DO, Division of Rheumatology, University of Pittsburgh; C.A. McAlear, MA, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; P.A. Monach, MD, PhD, The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine; P. Seo, MD, MHS, Division of Rheumatology, Johns Hopkins University; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic College of Medicine; S.R. Ytterberg, MD, Division of Rheumatology, Mayo Clinic College of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; E.L. Matteson, MD, MPH, Division of Rheumatology, Mayo Clinic College of Medicine. Address correspondence to Dr. T.A. Kermani, University of California, Los Angeles, 2020 Santa Monica Blvd., Suite 540, Santa Monica, California 90404, USA. E-mail: kermani.tanaz@yahoo.com. Accepted for publication February 26, 2016.
Carol A. McAlear
From the Division of Rheumatology, University of California, Los Angeles, Los Angeles, California; Department of Biostatistics, University of South Florida, Tampa, Florida, USA; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada; Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio, USA; Division of Rheumatology, St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario, Canada; Division of Rheumatology, University of Utah, Salt Lake City, Utah; Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Division of Rheumatology and Clinical Immunology, University of Pennsylvania, Philadelphia, Pennsylvania; The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Dr. Kermani was supported through a Vasculitis Fellowship by the Vasculitis Clinical Research Consortium (VCRC). The VCRC has received support from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the US National Center for Research Resources (U54 RR019497), the Office of Rare Diseases Research, and the US National Center for Advancing Translational Science. The VCRC is part of the Rare Diseases Clinical Research Network. T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; D. Cuthbertson, MS, Department of Biostatistics, University of South Florida; S. Carette, MD, FRCPC, Division of Rheumatology, Mount Sinai Hospital; G.S. Hoffman, MD, MS, Center for Vasculitis Care and Research, Cleveland Clinic; N.A. Khalidi, MD, FRCPC, Division of Rheumatology, St. Joseph’s Healthcare, McMaster University; C.L. Koening, MD, MS, Division of Rheumatology, University of Utah; C.A. Langford, MD, MHS, Center for Vasculitis Care and Research, Cleveland Clinic; K. McKinnon-Maksimowicz, DO, Division of Rheumatology, University of Pittsburgh; C.A. McAlear, MA, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; P.A. Monach, MD, PhD, The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine; P. Seo, MD, MHS, Division of Rheumatology, Johns Hopkins University; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic College of Medicine; S.R. Ytterberg, MD, Division of Rheumatology, Mayo Clinic College of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; E.L. Matteson, MD, MPH, Division of Rheumatology, Mayo Clinic College of Medicine. Address correspondence to Dr. T.A. Kermani, University of California, Los Angeles, 2020 Santa Monica Blvd., Suite 540, Santa Monica, California 90404, USA. E-mail: kermani.tanaz@yahoo.com. Accepted for publication February 26, 2016.
Paul A. Monach
From the Division of Rheumatology, University of California, Los Angeles, Los Angeles, California; Department of Biostatistics, University of South Florida, Tampa, Florida, USA; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada; Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio, USA; Division of Rheumatology, St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario, Canada; Division of Rheumatology, University of Utah, Salt Lake City, Utah; Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Division of Rheumatology and Clinical Immunology, University of Pennsylvania, Philadelphia, Pennsylvania; The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Dr. Kermani was supported through a Vasculitis Fellowship by the Vasculitis Clinical Research Consortium (VCRC). The VCRC has received support from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the US National Center for Research Resources (U54 RR019497), the Office of Rare Diseases Research, and the US National Center for Advancing Translational Science. The VCRC is part of the Rare Diseases Clinical Research Network. T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; D. Cuthbertson, MS, Department of Biostatistics, University of South Florida; S. Carette, MD, FRCPC, Division of Rheumatology, Mount Sinai Hospital; G.S. Hoffman, MD, MS, Center for Vasculitis Care and Research, Cleveland Clinic; N.A. Khalidi, MD, FRCPC, Division of Rheumatology, St. Joseph’s Healthcare, McMaster University; C.L. Koening, MD, MS, Division of Rheumatology, University of Utah; C.A. Langford, MD, MHS, Center for Vasculitis Care and Research, Cleveland Clinic; K. McKinnon-Maksimowicz, DO, Division of Rheumatology, University of Pittsburgh; C.A. McAlear, MA, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; P.A. Monach, MD, PhD, The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine; P. Seo, MD, MHS, Division of Rheumatology, Johns Hopkins University; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic College of Medicine; S.R. Ytterberg, MD, Division of Rheumatology, Mayo Clinic College of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; E.L. Matteson, MD, MPH, Division of Rheumatology, Mayo Clinic College of Medicine. Address correspondence to Dr. T.A. Kermani, University of California, Los Angeles, 2020 Santa Monica Blvd., Suite 540, Santa Monica, California 90404, USA. E-mail: kermani.tanaz@yahoo.com. Accepted for publication February 26, 2016.
Philip Seo
From the Division of Rheumatology, University of California, Los Angeles, Los Angeles, California; Department of Biostatistics, University of South Florida, Tampa, Florida, USA; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada; Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio, USA; Division of Rheumatology, St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario, Canada; Division of Rheumatology, University of Utah, Salt Lake City, Utah; Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Division of Rheumatology and Clinical Immunology, University of Pennsylvania, Philadelphia, Pennsylvania; The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Dr. Kermani was supported through a Vasculitis Fellowship by the Vasculitis Clinical Research Consortium (VCRC). The VCRC has received support from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the US National Center for Research Resources (U54 RR019497), the Office of Rare Diseases Research, and the US National Center for Advancing Translational Science. The VCRC is part of the Rare Diseases Clinical Research Network. T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; D. Cuthbertson, MS, Department of Biostatistics, University of South Florida; S. Carette, MD, FRCPC, Division of Rheumatology, Mount Sinai Hospital; G.S. Hoffman, MD, MS, Center for Vasculitis Care and Research, Cleveland Clinic; N.A. Khalidi, MD, FRCPC, Division of Rheumatology, St. Joseph’s Healthcare, McMaster University; C.L. Koening, MD, MS, Division of Rheumatology, University of Utah; C.A. Langford, MD, MHS, Center for Vasculitis Care and Research, Cleveland Clinic; K. McKinnon-Maksimowicz, DO, Division of Rheumatology, University of Pittsburgh; C.A. McAlear, MA, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; P.A. Monach, MD, PhD, The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine; P. Seo, MD, MHS, Division of Rheumatology, Johns Hopkins University; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic College of Medicine; S.R. Ytterberg, MD, Division of Rheumatology, Mayo Clinic College of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; E.L. Matteson, MD, MPH, Division of Rheumatology, Mayo Clinic College of Medicine. Address correspondence to Dr. T.A. Kermani, University of California, Los Angeles, 2020 Santa Monica Blvd., Suite 540, Santa Monica, California 90404, USA. E-mail: kermani.tanaz@yahoo.com. Accepted for publication February 26, 2016.
Kenneth J. Warrington
From the Division of Rheumatology, University of California, Los Angeles, Los Angeles, California; Department of Biostatistics, University of South Florida, Tampa, Florida, USA; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada; Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio, USA; Division of Rheumatology, St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario, Canada; Division of Rheumatology, University of Utah, Salt Lake City, Utah; Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Division of Rheumatology and Clinical Immunology, University of Pennsylvania, Philadelphia, Pennsylvania; The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Dr. Kermani was supported through a Vasculitis Fellowship by the Vasculitis Clinical Research Consortium (VCRC). The VCRC has received support from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the US National Center for Research Resources (U54 RR019497), the Office of Rare Diseases Research, and the US National Center for Advancing Translational Science. The VCRC is part of the Rare Diseases Clinical Research Network. T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; D. Cuthbertson, MS, Department of Biostatistics, University of South Florida; S. Carette, MD, FRCPC, Division of Rheumatology, Mount Sinai Hospital; G.S. Hoffman, MD, MS, Center for Vasculitis Care and Research, Cleveland Clinic; N.A. Khalidi, MD, FRCPC, Division of Rheumatology, St. Joseph’s Healthcare, McMaster University; C.L. Koening, MD, MS, Division of Rheumatology, University of Utah; C.A. Langford, MD, MHS, Center for Vasculitis Care and Research, Cleveland Clinic; K. McKinnon-Maksimowicz, DO, Division of Rheumatology, University of Pittsburgh; C.A. McAlear, MA, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; P.A. Monach, MD, PhD, The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine; P. Seo, MD, MHS, Division of Rheumatology, Johns Hopkins University; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic College of Medicine; S.R. Ytterberg, MD, Division of Rheumatology, Mayo Clinic College of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; E.L. Matteson, MD, MPH, Division of Rheumatology, Mayo Clinic College of Medicine. Address correspondence to Dr. T.A. Kermani, University of California, Los Angeles, 2020 Santa Monica Blvd., Suite 540, Santa Monica, California 90404, USA. E-mail: kermani.tanaz@yahoo.com. Accepted for publication February 26, 2016.
Steven R. Ytterberg
From the Division of Rheumatology, University of California, Los Angeles, Los Angeles, California; Department of Biostatistics, University of South Florida, Tampa, Florida, USA; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada; Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio, USA; Division of Rheumatology, St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario, Canada; Division of Rheumatology, University of Utah, Salt Lake City, Utah; Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Division of Rheumatology and Clinical Immunology, University of Pennsylvania, Philadelphia, Pennsylvania; The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Dr. Kermani was supported through a Vasculitis Fellowship by the Vasculitis Clinical Research Consortium (VCRC). The VCRC has received support from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the US National Center for Research Resources (U54 RR019497), the Office of Rare Diseases Research, and the US National Center for Advancing Translational Science. The VCRC is part of the Rare Diseases Clinical Research Network. T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; D. Cuthbertson, MS, Department of Biostatistics, University of South Florida; S. Carette, MD, FRCPC, Division of Rheumatology, Mount Sinai Hospital; G.S. Hoffman, MD, MS, Center for Vasculitis Care and Research, Cleveland Clinic; N.A. Khalidi, MD, FRCPC, Division of Rheumatology, St. Joseph’s Healthcare, McMaster University; C.L. Koening, MD, MS, Division of Rheumatology, University of Utah; C.A. Langford, MD, MHS, Center for Vasculitis Care and Research, Cleveland Clinic; K. McKinnon-Maksimowicz, DO, Division of Rheumatology, University of Pittsburgh; C.A. McAlear, MA, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; P.A. Monach, MD, PhD, The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine; P. Seo, MD, MHS, Division of Rheumatology, Johns Hopkins University; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic College of Medicine; S.R. Ytterberg, MD, Division of Rheumatology, Mayo Clinic College of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; E.L. Matteson, MD, MPH, Division of Rheumatology, Mayo Clinic College of Medicine. Address correspondence to Dr. T.A. Kermani, University of California, Los Angeles, 2020 Santa Monica Blvd., Suite 540, Santa Monica, California 90404, USA. E-mail: kermani.tanaz@yahoo.com. Accepted for publication February 26, 2016.
Peter A. Merkel
From the Division of Rheumatology, University of California, Los Angeles, Los Angeles, California; Department of Biostatistics, University of South Florida, Tampa, Florida, USA; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada; Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio, USA; Division of Rheumatology, St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario, Canada; Division of Rheumatology, University of Utah, Salt Lake City, Utah; Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Division of Rheumatology and Clinical Immunology, University of Pennsylvania, Philadelphia, Pennsylvania; The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Dr. Kermani was supported through a Vasculitis Fellowship by the Vasculitis Clinical Research Consortium (VCRC). The VCRC has received support from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the US National Center for Research Resources (U54 RR019497), the Office of Rare Diseases Research, and the US National Center for Advancing Translational Science. The VCRC is part of the Rare Diseases Clinical Research Network. T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; D. Cuthbertson, MS, Department of Biostatistics, University of South Florida; S. Carette, MD, FRCPC, Division of Rheumatology, Mount Sinai Hospital; G.S. Hoffman, MD, MS, Center for Vasculitis Care and Research, Cleveland Clinic; N.A. Khalidi, MD, FRCPC, Division of Rheumatology, St. Joseph’s Healthcare, McMaster University; C.L. Koening, MD, MS, Division of Rheumatology, University of Utah; C.A. Langford, MD, MHS, Center for Vasculitis Care and Research, Cleveland Clinic; K. McKinnon-Maksimowicz, DO, Division of Rheumatology, University of Pittsburgh; C.A. McAlear, MA, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; P.A. Monach, MD, PhD, The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine; P. Seo, MD, MHS, Division of Rheumatology, Johns Hopkins University; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic College of Medicine; S.R. Ytterberg, MD, Division of Rheumatology, Mayo Clinic College of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; E.L. Matteson, MD, MPH, Division of Rheumatology, Mayo Clinic College of Medicine. Address correspondence to Dr. T.A. Kermani, University of California, Los Angeles, 2020 Santa Monica Blvd., Suite 540, Santa Monica, California 90404, USA. E-mail: kermani.tanaz@yahoo.com. Accepted for publication February 26, 2016.
Eric L. Matteson
From the Division of Rheumatology, University of California, Los Angeles, Los Angeles, California; Department of Biostatistics, University of South Florida, Tampa, Florida, USA; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada; Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio, USA; Division of Rheumatology, St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario, Canada; Division of Rheumatology, University of Utah, Salt Lake City, Utah; Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania; Division of Rheumatology and Clinical Immunology, University of Pennsylvania, Philadelphia, Pennsylvania; The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Dr. Kermani was supported through a Vasculitis Fellowship by the Vasculitis Clinical Research Consortium (VCRC). The VCRC has received support from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the US National Center for Research Resources (U54 RR019497), the Office of Rare Diseases Research, and the US National Center for Advancing Translational Science. The VCRC is part of the Rare Diseases Clinical Research Network. T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; D. Cuthbertson, MS, Department of Biostatistics, University of South Florida; S. Carette, MD, FRCPC, Division of Rheumatology, Mount Sinai Hospital; G.S. Hoffman, MD, MS, Center for Vasculitis Care and Research, Cleveland Clinic; N.A. Khalidi, MD, FRCPC, Division of Rheumatology, St. Joseph’s Healthcare, McMaster University; C.L. Koening, MD, MS, Division of Rheumatology, University of Utah; C.A. Langford, MD, MHS, Center for Vasculitis Care and Research, Cleveland Clinic; K. McKinnon-Maksimowicz, DO, Division of Rheumatology, University of Pittsburgh; C.A. McAlear, MA, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; P.A. Monach, MD, PhD, The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine; P. Seo, MD, MHS, Division of Rheumatology, Johns Hopkins University; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic College of Medicine; S.R. Ytterberg, MD, Division of Rheumatology, Mayo Clinic College of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology and Clinical Immunology, University of Pennsylvania; E.L. Matteson, MD, MPH, Division of Rheumatology, Mayo Clinic College of Medicine. Address correspondence to Dr. T.A. Kermani, University of California, Los Angeles, 2020 Santa Monica Blvd., Suite 540, Santa Monica, California 90404, USA. E-mail: kermani.tanaz@yahoo.com. Accepted for publication February 26, 2016.
Roles: for the Vasculitis Clinical Research Consortium
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis
Tanaz A. Kermani, David Cuthbertson, Simon Carette, Gary S. Hoffman, Nader A. Khalidi, Curry L. Koening, Carol A. Langford, Kathleen McKinnon-Maksimowicz, Carol A. McAlear, Paul A. Monach, Philip Seo, Kenneth J. Warrington, Steven R. Ytterberg, Peter A. Merkel, Eric L. Matteson
The Journal of Rheumatology Apr 2016, jrheum.151063; DOI: 10.3899/jrheum.151063
The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis
Tanaz A. Kermani, David Cuthbertson, Simon Carette, Gary S. Hoffman, Nader A. Khalidi, Curry L. Koening, Carol A. Langford, Kathleen McKinnon-Maksimowicz, Carol A. McAlear, Paul A. Monach, Philip Seo, Kenneth J. Warrington, Steven R. Ytterberg, Peter A. Merkel, Eric L. Matteson
The Journal of Rheumatology Apr 2016, jrheum.151063; DOI: 10.3899/jrheum.151063